TXMD - TherapeuticsMD Inc Stock Price, Fair Value and News

2.24USD+0.12 (+5.66%)Market Closed

Market Summary

USD2.24+0.12

Market Closed

5.66%

TXMD Stock Price

View Fullscreen

TXMD RSI Chart

TXMD Valuation

Market Cap

25.8M

Price/Earnings (Trailing)

-3.49

Price/Sales (Trailing)

19.84

EV/EBITDA

-4.04

Price/Free Cashflow

-1.77

TXMD Price/Sales (Trailing)

TXMD Profitability

EBT Margin

-479.34%

Return on Equity

-25.85%

Return on Assets

-17.6%

Free Cashflow Yield

-56.55%

TXMD Fundamentals

TXMD Revenue

Revenue (TTM)

1.3M

TXMD Earnings

Earnings (TTM)

-7.4M

Breaking Down TXMD Revenue

Last 7 days

10.3%

Last 30 days

18.5%

Last 90 days

-0.9%

Trailing 12 Months

-47.2%

How does TXMD drawdown profile look like?

TXMD Financial Health

Current Ratio

1.78

TXMD Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	52.8M	35.6M	18.5M	1.3M
2022	67.8M	45.1M	57.5M	70.0M
2021	72.5M	84.8M	90.9M	87.0M
2020	58.0M	62.6M	58.2M	64.9M
2019	16.3M	18.6M	38.8M	49.6M
2018	16.6M	16.1M	15.1M	16.1M
2017	18.4M	18.3M	17.1M	16.8M
2016	20.6M	20.2M	20.5M	19.4M
2015	16.7M	17.8M	18.8M	20.1M
2014	10.3M	11.7M	13.6M	15.0M
2013	0	5.5M	7.1M	8.8M
2012	2.3M	2.6M	3.1M	3.8M
2011	1.5M	1.7M	1.9M	2.1M
2010	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of TherapeuticsMD Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 07, 2023	walker marlan d	sold	-10,187	2.239	-4,550	chief executive officer
Dec 06, 2023	walker marlan d	sold	-33,496	2.3101	-14,500	chief executive officer
Dec 05, 2023	walker marlan d	acquired	-	-	70,000	chief executive officer
Nov 15, 2023	rubric capital management lp	acquired	2,000,000	2.28	877,192	-
Aug 17, 2023	ziegler joseph	acquired	-	-	7,500	principal financial officer
Jun 28, 2023	rubric capital management lp	acquired	1,150,000	3.6797	312,525	-
Apr 26, 2023	walker marlan d	sold	-2,517	3.6381	-692	chief executive officer
Apr 26, 2023	walker marlan d	acquired	-	-	2,744	chief executive officer
Apr 12, 2023	walker marlan d	sold	-4,275	3.6543	-1,170	chief executive officer
Apr 12, 2023	donegan michael c	acquired	-	-	50,000	prin. fin. and acctg. officer

Which funds bought or sold TXMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	new	-	11,363	11,363	-%
May 15, 2024	STATE STREET CORP	unchanged	-	1,204	68,929	-%
May 15, 2024	MORGAN STANLEY	reduced	-0.06	5,099	301,575	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-2.2	-4.00	916	-%
May 15, 2024	BARCLAYS PLC	sold off	-100	-	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	14,781	3,724	3,749	-%
May 15, 2024	ADAR1 Capital Management, LLC	unchanged	-	10,886	623,246	0.14%
May 15, 2024	Royal Bank of Canada	added	235	1,000	1,000	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-6.9	-4,961	89,539	-%
May 15, 2024	Clearline Capital LP	added	14.83	176,954	1,225,930	0.06%

Are Funds Buying or Selling TXMD?

Are funds buying TXMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TXMD

No. of Funds

Unveiling TherapeuticsMD Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 17, 2023	rubric capital management lp	25.73%	2,946,908	SC 13D/A
Jun 30, 2023	rubric capital management lp	19.57%	2,069,716	SC 13D/A
Aug 30, 2022	rubric capital management lp	18.27%	1,721,953	SC 13D/A
Jul 08, 2022	blackrock inc.	1.4%	122,138	SC 13G/A
Jun 03, 2022	beryl capital management llc	1.5%	126,229	SC 13G
Mar 23, 2022	smith robert j	5.38%	23,103,292	SC 13D/A
Feb 14, 2022	price t rowe associates inc /md/	0.1%	649,807	SC 13G/A
Feb 01, 2022	blackrock inc.	5.9%	24,894,812	SC 13G/A
Jul 07, 2021	flynn james e	4.90%	20,662,810	SC 13G
Feb 16, 2021	price t rowe associates inc /md/	6.2%	18,869,212	SC 13G/A

Recent SEC filings of TherapeuticsMD Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K	Current Report
May 10, 2024	10-Q	Quarterly Report
Apr 29, 2024	10-K/A	Annual Report
Mar 29, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report

Peers (Alternatives to TherapeuticsMD Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

TherapeuticsMD Inc News

Latest updates

TherapeuticsMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	6.9%	502,000	469,500	437,000	414,750	392,500	370,250	348,000	695,000	18,678,000	25,406,000	23,001,000	19,866,000	22,578,000	19,342,000	10,701,000	12,251,000	15,902,000	23,719,000	6,079,000	3,947,000	5,089,000
Gross Profit	1047.2%	502,000	-53,000	437,000	416,000	61,329,500	-	-	14,473,000	13,941,000	20,124,000	18,869,000	15,179,000	16,997,000	16,063,000	6,301,000	9,536,000	13,023,000	22,275,000	4,830,000	3,184,000	4,139,000
Operating Expenses	22.8%	2,113,000	1,720,000	2,909,000	3,083,000	20,124,000	14,519,000	14,857,000	17,875,000	-77,802,000	60,045,000	54,048,000	44,457,000	51,604,000	41,037,000	51,339,000	60,458,000	57,414,537	49,346,683	46,466,878	41,288,902	42,259,406
S&GA Expenses	-7.2%	1,476,000	1,590,000	2,781,000	3,056,000	10,343,000	14,246,000	14,575,000	17,546,000	-5,445,000	30,005,000	32,164,000	24,024,000	16,799,500	22,373,000	29,887,000	57,189,000	-7,147,519	45,126,986	41,387,451	34,864,082	35,410,875
R&D Expenses	-	-	-	-	-	-	1,112,000	1,580,000	1,400,000	1,420,000	1,605,000	2,011,000	2,050,000	2,394,000	2,027,000	2,742,000	3,269,000	4,432,012	4,077,738	4,964,368	6,317,882	6,753,190
EBITDA Margin	-279.6%	-5.24	2.92	1.14	0.54	0.26	0.11	-0.40	-0.55	-0.62	-1.47	-1.41	-1.80	-2.34	-	-	-	-	-	-	-	-
Interest Expenses	-675.0%	-115,000	20,000	45,000	50,000	10,863,000	-	-	5,364,000	-273,000	7,518,000	7,596,000	10,227,000	7,612,000	7,680,000	7,027,000	6,262,000	5,664,368	5,599,005	4,028,609	2,090,018	2,093,375
Income Taxes	-	-	-	-	-	-295,000	-260,000	550,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-10.5%	-1,584,000	-1,434,000	-2,414,000	-2,310,000	48,453,000	-14,631,000	-14,873,000	-17,875,000	50,150,000	-47,420,000	-42,652,000	-39,383,000	-42,087,000	-32,612,000	-51,976,000	-56,849,000	-49,435,515	-31,966,593	-55,236,517	-39,506,375	-39,390,981
EBT Margin	-359.6%	-5.95	2.29	0.82	0.32	0.02	0.05	-0.67	-0.85	-0.91	-1.89	-1.85	-2.29	-2.83	-	-	-	-	-	-	-	-
Net Income	73.9%	-883,000	-3,378,000	-2,414,000	-3,603,000	77,702,000	-28,965,000	112,281,000	-49,021,000	-42,960,000	-47,420,000	-42,652,000	-39,383,000	-42,087,000	-32,612,000	-51,976,000	-56,849,000	-49,435,000	-31,967,000	-55,237,000	-39,506,000	-39,391,000
Net Income Margin	-313.4%	-7.89	3.70	1.20	2.98	1.60	-0.15	-0.60	-2.69	-1.98	-1.89	-1.85	-2.29	-2.83	-	-	-	-	-	-	-	-
Free Cashflow	17.7%	-4,960,000	-6,028,000	-3,392,000	-8,701,000	30,236,000	17,716,000	-20,700,000	-17,914,000	48,002,000	-38,153,000	-26,573,000	-38,443,000	-30,525,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.8%	42.00	43.00	50.00	54.00	60.00	90.00	134	146	133	169	210	211	239	182	177	206	269	266	250	247	182
Current Assets	-2.3%	12.00	12.00	17.00	20.00	25.00	55.00	87.00	99.00	84.00	119	160	160	187	128	122	149	212	208	192	216	153
Cash Equivalents	-100.0%	-	4.00	49.00	49.00	49.00	49.00	65.00	65.00	65.00	65.00	105	111	138	80.00	80.00	114	170	161	155	183	123
Inventory	-	-	-	-	-	-	-	7.00	6.00	9.00	8.00	7.00	8.00	7.00	8.00	10.00	10.00	15.00	12.00	11.00	7.00	5.00
Net PPE	-	-	-	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00	1.00	1.00
Liabilities	-4.3%	13.00	14.00	22.00	22.00	28.00	55.00	182	172	274	263	267	260	249	306	293	300	314	257	271	238	121
Current Liabilities	-5.6%	6.00	7.00	15.00	14.00	19.00	47.00	174	164	265	253	86.00	76.00	61.00	59.00	47.00	46.00	62.00	53.00	67.00	42.00	45.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	172	175	179	238	237	244	243	195	194	194	74.00
LT Debt, Current	-	-	-	-	-	-	-	94.00	91.00	203	188	15.00	10.00	5.00	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	172	175	179	238	237	244	243	195	194	194	74.00
Shareholder's Equity	-2.1%	29.00	29.00	28.00	31.00	32.00	35.00	-	-	-	-93.62	-	-	-	-	-	-	-	9.00	-	8.00	61.00
Retained Earnings	-0.1%	-950	-949	-948	-945	-942	-939	-1,017	-988	-1,100	-1,051	-1,008	-960	-918	-878	-836	-804	-752	-695	-645	-614	-558
Additional Paid-In Capital	0.0%	979	979	977	977	975	974	969	962	960	958	951	912	908	755	721	710	707	704	625	622	619
Accumulated Depreciation	-100.0%	-	3.00	-	-	-	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.0%	12.00	12.00	11.00	11.00	10.00	9.00	9.00	9.00	9.00	9.00	8.00	8.00	7.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	34.00	-	-	-	87.00	-	-	-	445	-	-	-	308	-	-	-	539	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	95.4%	-229	-4,960	-6,028	-3,392	-8,701	30,236	17,716	-20,721	-17,872	48,002	-38,223	-26,532	-38,380	-30,357	-34,049	-55,954	-39,111	-50,817	-26,222	-50,514	-38,163
Share Based Compensation	-4.3%	111	116	234	438	483	2,985	4,292	2,234	2,061	5,346	7,312	2,510	2,957	5,245	-	-	2,366	5,403	56.00	56.00	2,587
Cashflow From Investing	-	-	-	-	-	-	-74.00	7.00	-76.00	-212	-1,514	-182	-89.00	-438	-494	-262	-399	-443	-20,713	-1,302	-1,210	-665
Cashflow From Financing	-100.0%	-	2,002	-1.00	-	-	-111,945	1,739	-120,000	-5,000	1,353	31,822	428	95,949	31,703	106	94.00	48,822	77,031	9.00	111,687	100

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TXMD Income Statement

2024-03-31

Condensed Consolidated Statements of Comprehensive (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Selling, general and administrative	$ 1,322	$ 3,056
Depreciation & amortization	133	27
Total operating expenses	1,455	3,083
Loss from operations	(1,142)	(2,667)
Other income (expense) :
Interest expense and other financing costs		(50)
Miscellaneous income (expense)	333	407
Total other income, net	333	357
Loss from continuing operations before income taxes	(809)	(2,310)
Provision for income taxes
Loss from continuing operations, net of income taxes	(809)	(2,310)
Income (loss) from discontinued operations, net of income taxes	75	(1,293)
Net loss	$ (734)	$ (3,603)
Income (loss) per common share, basic and diluted:
Continuing operations (in Dollars per share)	$ (0.07)	$ (0.24)
Discontinued operations, net (in Dollars per share)	0.01	(0.13)
Net loss per common share, basic (in Dollars per share)	$ (0.06)	$ (0.37)
Weighted average common shares, basic (in Shares)	11,532,000	9,754,000
Weighted average common shares, diluted (in Shares)	11,532,000	9,754,000
License and service revenue
Revenue, net:
License and service revenue	$ 313	$ 416

TXMD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,338	$ 4,327
Royalty receivable, current portion	3,222	3,090
Prepaid and other current assets	3,869	4,035
Current assets of discontinued operations	94	344
Total current assets	11,523	11,796
License rights and other intangible assets, net	5,965	6,098
Right of use assets	6,687	6,873
Royalty receivable, long term	17,855	18,484
Other non-current assets	58	58
Total assets	42,088	43,309
Current liabilities:
Accounts payable	139	27
Accrued expenses and other current liabilities	2,720	3,133
Current liabilities of discontinued operations	3,609	3,694
Total current liabilities	6,468	6,854
Operating lease liabilities	6,319	6,532
Other non-current liabilities	637	636
Total liabilities	13,424	14,022
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, par value $0.001; 32,000 shares authorized, 11,532 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	11	11
Additional paid-in capital	979,028	978,917
Accumulated deficit	(950,375)	(949,641)
Total stockholders’ equity	28,664	29,287
Total liabilities and stockholders’ equity	$ 42,088	$ 43,309

About TherapeuticsMD Inc

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

WEBSITE	therapeuticsmd.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1

TherapeuticsMD Inc Frequently Asked Questions

What is the ticker symbol for TherapeuticsMD Inc? What does TXMD stand for in stocks?

TXMD is the stock ticker symbol of TherapeuticsMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of TherapeuticsMD Inc (TXMD)?

As of Fri May 17 2024, market cap of TherapeuticsMD Inc is 25.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TXMD stock?

You can check TXMD's fair value in chart for subscribers.

What is the fair value of TXMD stock?

You can check TXMD's fair value in chart for subscribers. The fair value of TherapeuticsMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of TherapeuticsMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TXMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is TherapeuticsMD Inc a good stock to buy?

The fair value guage provides a quick view whether TXMD is over valued or under valued. Whether TherapeuticsMD Inc is cheap or expensive depends on the assumptions which impact TherapeuticsMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXMD.

What is TherapeuticsMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TXMD's PE ratio (Price to Earnings) is -3.49 and Price to Sales (PS) ratio is 19.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on TherapeuticsMD Inc's stock?

In the past 10 years, TherapeuticsMD Inc has provided -0.357 (multiply by 100 for percentage) rate of return.